Evidence map›Paper›PMID 42347972›Full record

ArticleClinical and experimental medicine2026

Decoding the immunometabolic landscape identifies SLC7A5 as a vulnerability in chemo-immunotherapy resistant TNBC.

Sen Zhong, Bolin Yu, Shengyi Zhou, Wenlong Chen, Fanglong Liu, Huanhuan Zhu, Fang Min, Fengyuan Qian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sen Zhong *School of Medicine, Department of Breast and Thyroid Surgery, Tongji University, Shanghai Tenth People's Hospital, 301 Yanchang Middle Road, 200072, Shanghai, China.
Bolin Yu *School of Medicine, Department of Breast and Thyroid Surgery, Tongji University, Shanghai Tenth People's Hospital, 301 Yanchang Middle Road, 200072, Shanghai, China.
Shengyi Zhou *School of Medicine, Department of Breast and Thyroid Surgery, Tongji University, Shanghai Tenth People's Hospital, 301 Yanchang Middle Road, 200072, Shanghai, China.
Wenlong ChenSchool of Medicine, Department of Breast and Thyroid Surgery, Tongji University, Shanghai Tenth People's Hospital, 301 Yanchang Middle Road, 200072, Shanghai, China.
Fanglong LiuDepartment of Thyroid and Breast Surgery, Shanghai Tenth People's Hospital, Clinical Medical College of Nanjing Medical University, Shanghai, 200072, China.
Huanhuan ZhuCentral Laboratory, Shanghai Tenth People'sHospital, Tongji University, Shanghai, 200072, China.
Fang MinDepartment of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai, 200433, China. fangmin0530@163.com.
Fengyuan QianSchool of Medicine, Department of Breast and Thyroid Surgery, Tongji University, Shanghai Tenth People's Hospital, 301 Yanchang Middle Road, 200072, Shanghai, China. qianfengyuan876@163.com.ORCID http://orcid.org/0000-0002-0558-8793

Funding

Shanghai Municipal Education Commission 25CGA21
6 · The paper itself

Abstract

Metabolic reprogramming within the tumor microenvironment (TME) limits the efficacy of chemo-immunotherapy in triple-negative breast cancer (TNBC). Despite advances in high-resolution profiling, the specific intercellular metabolic crosstalk driving immune evasion remains incompletely understood. Here, we present a comprehensive single-cell metabolic atlas of the TNBC ecosystem to decode spatial and cell-type-specific metabolic vulnerabilities. Our multidimensional analysis reveals a distinct paracrine metabolic communication axis: CXCL9

Indexed as

Drug Resistance, NeoplasmTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCisplatinCoculture TechniquesFemaleHumansImmunotherapyKynurenineLarge Neutral Amino Acid-Transporter 1MacrophagesMetabolic ReprogrammingMiceTumor MicroenvironmentCisplatinKynurenineLarge Neutral Amino Acid-Transporter 1SLC7A5 protein, humanChemo-immunotherapy resistanceImmunometabolismKynurenineMetabolic reprogrammingTumor microenvironment

Identifiers

PMID42347972
PMCPMC13553622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.